GTC
VIRX

Ghost Tree Capital’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Ghost Tree Capital’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,395
Closed -$237K – 70
2015
Q3 		$237K Sell
1,395
-4,557
-77% -$1.64M 0.11% 74
2015
Q2 		$3.76M Sell
5,952
-2,381
-29% -$1.27M 1.22% 38
2015
Q1 		$4.29M Buy
+8,333
New +$4.2M 1.54% 23

Other funds holding VIRX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ghost Tree Capital's VIRX Position: Q4 2015 in Review

Ghost Tree Capital sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2015, closing a stake of 1,395 shares — an estimated $237K sold.

Ghost Tree Capital first reported a position in VIRX in Q1 2015 and held it in 3 quarters. The position peaked at $4.29M in Q1 2015. 55 funds tracked by Wall St. Rank hold VIRX as of Q4 2015.

  • Ghost Tree Capital reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Ghost Tree Capital sold 1,395 Viracta Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $237K.
  • Ghost Tree Capital first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2015 and held it in 3 quarters.
  • Ghost Tree Capital's Viracta Therapeutics, Inc. Common Stock position peaked at $4.29M in Q1 2015.
  • 55 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2015.

Based on Ghost Tree Capital's 13F filing for Q4 2015, filed 16 Feb 2016.